Answers are grounded in this paper and cite their sources.
Meta-analysis evaluates SGLT2 inhibitors' effect on Parkinson’s disease risk in patients with specific conditions, suggesting potential implications.
To evaluate whether sodium-glucose cotransporter-2 (SGLT2) inhibitors influence the risk of Parkinson’s disease (PD) in patients with diabetes, heart failure, or chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Alexander et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: